-
Kizdar net |
Kizdar net |
Кыздар Нет
FDA Accepts NDA for TLX101-Px (Pixclara®) - Telix Pharmaceuticals ...
TLX101-Px is a PET imaging candidate, which has been granted Fast Track and Orphan Drug designations by the FDA for the …
TLX PDUFA 日历：FDA 决策日期与催化剂时间线
Aug 17, 2026 · 本页汇总与 Telix Pharmaceuticals Ltd 相关的有效 PDUFA 和 FDA 决策里程碑。 可将其作为该股票的监管时间线，并 …
Telix and FDA Agree on Resubmission Pathway for TLX101-CDx …
Sep 9, 2025 · Following engagement with the FDA, including a successful Type A meeting, Telix has received detailed feedback …
Telix Pharmaceuticals：FDA受理Pixclara®新药申请，PDUFA日期定为2026年9月11日
新时空讯，据4月10日新加坡交易所公告，Telix Pharmaceuticals宣布美国FDA已受理其Pixclara®（TLX101-Px）的重新提交新药申 …
TLX PDUFA date: TLX101-Px, Sep 11 2026 | pdufa.bio
Jun 29, 2026 · TLX101-Px is under FDA review for PET imaging to characterise recurrent or progressive glioma from treatment …
Telix Pharmaceuticals Limited (TLX) FDA Catalysts | pdufa.bio
Mar 21, 2025 · How do stocks like TLX move into an FDA decision? We have no measured history for TLX itself. Across the whole …
標題 : Telix腦癌影像劑TLX101‑Px獲FDA受理，股價盤前衝高約7% — 審查目標日定2026/9/11
摘要 : 美國FDA接受Telix對腦癌PET造影劑TLX101‑Px的再提交申請，審查期限為2026年9月11日。 新聞 : 開頭引人注意： 澳洲生技 …
Telix NDA for glioma imaging drug accepted by FDA
Apr 10, 2026 · Telix Pharmaceuticals reports that the U.S. FDA has accepted its resubmitted New Drug Application for TLX101-Px …
Telix Pharmaceuticals Limited, FDA Calendar, PDUFA Date
1 day ago · FDA issued complete response letter for TLX101-Px, proposed as an agent for the imaging of glioma, in April 2025. Telix …
TLX PDUFA Calendar: FDA Decision Dates & Catalyst Timeline
Apr 28, 2025 · This page gathers active PDUFA and FDA decision milestones connected to Telix Pharmaceuticals Ltd. Use it as a …
Skip to content
Accessibility Feedback